scPharmaceuticals Inc..
SCPH.US | Manufacture of pharmaceuticals, medicinal chemical and botanical products
scPharmaceuticals Inc. is a pharmaceutical company focused on developing and commercializing products that enable subcutaneous delivery of injectable medicines. Their primary focus is on therapies for heart failure and other conditions where subcutaneous administration offers advantages over intrave...Show More
Better Health for All
-20
scPharmaceuticals' primary product, FUROSCIX, delivers exceptional health benefits by reducing 30-day heart failure-related costs by $16,995 per patient
1
and has expanded its indication to include chronic kidney disease
2
, with the entire business devoted to health improvement. The company does not generate revenue from products with established negative health outcomes. However, the product's safety record indicates that 29.2% of patients experienced infusion site bruising and pain, and 12.5% experienced dizziness in clinical trials.
3
While 9 serious adverse events occurred in 6 out of 24 patients, none were related to the study drug.
4
The company has made efforts to improve price accessibility by negotiating a fixed copay of $75 or less per prescription for over 9 million lives
5
and has added a specialty pharmacy to maximize access for national Medicaid beneficiaries.
6
Risk transparency is addressed by making full prescribing information and instructions for use available online.
7
The company's R&D expenses were $3.4 million in Q3 2023,
8
which is 89.5% of its $3.8 million product revenue.
9
The company also conducts in-services to educate physicians about FUROSCIX,
10
and its clinical trials were reviewed and approved by an Institutional Review Board, complying with the Declaration of Helsinki and ICH guidelines.
11
Fair Money & Economic Opportunity
0
scPharmaceuticals Inc. is a pharmaceutical company focused on developing and commercializing injectable medicines. The company does not offer lending, insurance, money movement, or storage services to consumers.
1
While it operates a Patient Assistance Program (PAP) for its FUROSCIX® medication, providing free medication to eligible US residents based on insurance and financial criteria, this program is focused on healthcare access rather than financial services.
2
Therefore, all KPIs related to financial products, lending, fees, debt, wealth building, and financial literacy are not applicable to the company's core business or its PAP.
3
Fair Pay & Worker Respect
0
The provided articles, which include financial results, clinical study outcomes, and employee reviews, do not contain specific, quantitative data points for any of the KPIs related to Fair Pay & Worker Respect. Several articles explicitly state a lack of data for metrics such as living wage coverage, CEO-to-median pay ratio, collective bargaining share, safety incident rate, pay equity ratio, worker engagement score, turnover rate, and insecure contract share.
1
While employee reviews mention competitive health insurance benefits and concerns about pay, they do not provide the required percentages or numerical scores for these KPIs.
2
There is also no quantitative data on labor violation incidents.
3
Fair Trade & Ethical Sourcing
0
No specific, quantitative evidence was found in the provided articles to assess scPharmaceuticals Inc. against any of the Fair Trade & Ethical Sourcing KPIs. pertains to SK Life Science, Inc., not scPharmaceuticals Inc. .
1
while about scPharmaceuticals Inc., explicitly states it contains no data relevant to fair trade, ethical sourcing, or supply chain metrics.
2
Honest & Fair Business
0
No evidence available to assess scPharmaceuticals Inc. on Honest & Fair Business.
Kind to Animals
0
No specific, concrete evidence was found in the provided articles regarding scPharmaceuticals Inc.'s performance on any of the 'Kind to Animals' KPIs. The articles primarily discuss general corporate information, SEC filings, clinical trial results, regulatory approvals for their products, and broader FDA policy changes regarding animal testing in the biopharma industry. There is no information on the company's cruelty-free certifications, alternative testing usage, humane certifications, wildlife conservation efforts, ethical input substitution, supplier audits, cage-free sourcing, animal testing policy or volume, innovation investment in animal-free technologies, animal agriculture ethics, animal-free R&D collaboration, or public policy engagement related to animal welfare.
1
No War, No Weapons
0
No evidence available to assess scPharmaceuticals Inc. on No War, No Weapons.
Planet-Friendly Business
0
No specific, quantitative data points for SCPH.US were found in the provided articles regarding its environmental performance. The articles either discuss other pharmaceutical companies' sustainability initiatives
1
, general industry trends in packaging
2
, or the services of a third-party waste management provider (Stericycle)
3
without attributing specific performance metrics to SCPH.US.
Respect for Cultures & Communities
0
No specific, concrete data points related to 'Respect for Cultures & Communities' were found in the provided articles. The articles primarily focus on financial performance, product development, and regulatory milestones for scPharmaceuticals Inc., such as FDA approvals for FUROSCIX® and various debt financing activities.
1
Safe & Smart Tech
0
No evidence available to assess scPharmaceuticals Inc. on Safe & Smart Tech.
Zero Waste & Sustainable Products
0
No evidence available to assess scPharmaceuticals Inc. on Zero Waste & Sustainable Products.